Viewing Study NCT03151057

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 6:46 PM
Ignite Modification Date: 2026-02-23 @ 8:08 PM
Study NCT ID: NCT03151057
Status: TERMINATED
Last Update Posted: 2024-03-12
First Post: 2017-03-29
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None B Cells-Tumors View
None B Cell Chronic Lymphocytic Leukemia View
None Follicular Lymphoma View
None Mantle Cell Lymphoma View
None Large B-Cell Diffuse Lymphoma of Bone (Diagnosis) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Idelalisib View
None Zydelig View
None allo transplant View
None PI3K inhibitor View
None post transplant maintenance therapy View